Renal dysfunction and risk of major adverse event and suboptimal control with vitamin K antagonists in a real life cohort of anticoagulated patients with non-valvular atrial fibrillation

27 August 2016 (00:00 - 00:00)

Organised by:

About the speaker

Doctor Carlos Pena Gil

University Hospital of Santiago de Compostela, Santiago de Compostela (Spain)

24 More presentations in this session

Presentation thumbnail

Patients with atrial fibrillation treated with apixaban are less likely to discontinue study drug when compared with warfarin: insights from the ARISTOTLE trial

Professor D. Xavier (Bangalore, IN)

Abstract Slides

Presentation thumbnail

Incidence of intracranial hemorrhage in the years 2013-15 in patients with atrial fibrillation in anticoagulant therapy: preliminary analysis of data from Ravenna registers

Doctor C. Gatti (Ravenna, IT)

Abstract Slides

Presentation thumbnail

High SAMe-TT2R2 score, labile INR and major adverse outcomes in a real life cohort of anticoagulated patients with non-valvular atrial fibrillation

Doctor D. Iglesias (Santiago de Compostela, ES)

Abstract Slides

Presentation thumbnail

CHA2DS2-Vasc score, as well as age and body mass index as the main risk factors of brain lesions in asymptomatic patients with paroxysmal non-valvular atrial fibrillation

Doctor J. Wieczorek (Katowice, PL)

Abstract Slides

Presentation thumbnail

Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation

Associate Professor A. Parwani (Berlin, DE)

Access the full session

Session thumbnail

Poster session 3 - Anticoagulation in atrial fibrillation III

The Event

ESC Congress 2016

27 August - 31 August 2016

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources